The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Authors
Rosa, Daniela DClamp, Andrew R
Mullamitha, Saifee A
Ton, Nhuan C
Lau, Sin C
Byrd, Louise M
Clayton, Richard D
Slade, Richard J
Kitchener, Henry C
Shanks, Jonathan H
Wilson, Gregory
McVey, Rhona J
Hasan, Jurjees
Swindell, Ric
Jayson, Gordon C
Affiliation
Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester. dornellesrosa@hotmail.comIssue Date
2006-06
Metadata
Show full item recordAbstract
BACKGROUND: To study the effect of the interval between surgery and the start of chemotherapy in the treatment of patients with advanced ovarian cancer. METHODS: We stratified patients according to the start of platinum-based chemotherapy in group 1 (within 4 weeks from surgery), group 2 (between 4 and 8 weeks) and group 3 (between 8 and 12 weeks). RESULTS: Three hundred and ninty-four stage III ovarian cancer patients were analysed. In the multivariate analysis there were no differences in survival according to the interval between surgery and chemotherapy among the three groups. The independent prognostic variables were type of procedure (p = 0.014), performance status (p = 0.040) and post-chemotherapy CA-125 (p < 0.0001). CONCLUSIONS: The interval between surgery and chemotherapy does not affect outcome.Citation
The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. 2006, 32 (5):588-91 Eur J Surg OncolJournal
European Journal of Surgical OncologyDOI
10.1016/j.ejso.2006.02.013PubMed ID
16569491Type
ArticleLanguage
enISSN
0748-7983ae974a485f413a2113503eed53cd6c53
10.1016/j.ejso.2006.02.013
Scopus Count
Related articles
- Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
- Authors: Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S, EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm
- Issue date: 2003 Jan 15
- International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
- Authors: Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM, International Collaborative Ovarian Neoplasm 1, European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm
- Issue date: 2003 Jan 15
- Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
- Authors: Akeson M, Zetterqvist BM, Dahllöf K, Brännström M, Horvath G
- Issue date: 2008
- Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
- Authors: García-Sáenz JA, Custodio A, Casado A, Vidart JA, Coronado PJ, Martín M, López-Tarruella S, Puente J, Fernández C, Díaz-Rubio E
- Issue date: 2011 Feb
- [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
- Authors: Mu T, Li XP, Wang JL, Wang SJ, Wang Y, Sun XL, Cui H, Wei LH
- Issue date: 2012 Aug